A2 Biotherapeutics is advancing precision cell therapies designed to more safely target cancer. During this discussion, President & CEO Jim Robinson discusses the company’s proprietary Tmod™ platform, recent clinical progress, and the opportunity to unlock new treatments for solid tumors. He also shares how A2 is working to bring greater precision, safety, and scalability to the next frontier of cancer care.

Soren Monroe-Anderson, Co-Founder & CEO of Neros Technologies, discusses Neros’ mission to build unmanned superiority at scale - advancing high-performance, cost-effective unmanned aerial systems while onshoring manufacturing to secure the U.S. supply chain. Founded in 2023, Neros is addressing a critical gap in both performance and production across modern defense technologies.

In this conversation, Karl Anderson, CEO and Founder of Lektra, outlines the company’s mission to rethink how energy is delivered, driving greater efficiency, reliability, and sustainability across the grid. With a clear vision for the future, Lektra is helping power the next generation of infrastructure.

Recludix joins Nasdaq’s The Signal in this conversation with Nancy Whiting, PharmD, CEO of Recludix Pharma, to share how the company is advancing transformative medicines for patients through innovative therapies targeting inflammatory diseases. The discussion explores its cutting-edge science, focus on previously undruggable protein targets, and the collaborative culture driving its next phase of growth.

Infinimmune focuses on building a next‑generation immunotherapy platform. In this conversation on The Signal, CEO and Founding Scientist Wyatt McDonnell shares the company’s founding thesis, the science behind its approach, and how the team is translating research into real clinical momentum. He also discusses the significance of Infinimmune’s recent licensing milestone and the priorities guiding the company’s next phase of growth.

At Nanoscope Therapeutics, the mission is clear: restore vision and improve quality of life for individuals facing retinal degeneration. With MCO‑010 - the first optogenetic investigational therapy to show potential vision restoration in clinical trials - the future is coming into focus. Hear from Sulagna Bhattacharya, CEO and Co-Founder, and Samarendra Mohanty, President, Chief Scientific Officer & Co-Founder on where it's headed.

Primmune Therapeutics is a clinical‑stage biotechnology company based in San Diego, California, focused on developing systemic cancer immunotherapies that activate the immune system in a precise and controlled way. In this episode, Charles (Charlie) McDermott, CEO & Director of Primmune Therapeutics, discusses the company’s mission to strengthen antitumor immunity, enhance the effectiveness of existing cancer treatments, and improve long‑term disease control by engaging both the innate and adaptive immune systems. Primmune’s approach is designed to generate durable immune responses against cancer - going beyond T‑cell activation alone. The company’s lead investigational program, PRTX007, is an orally administered small‑molecule TLR7 agonist engineered to drive coordinated immune activation. At the heart of Primmune’s work is the vision to bring powerful immunotherapies earlier in care and expand the opportunity to cure cancer for more patients worldwide.

In this episode of The Signal, Dr. Varun Sivaram, CEO and Founder of Emerald AI, discusses how the company is transforming AI data centers from burdens on the power grid into strategic assets. He shares Emerald AI’s long‑term vision to strengthen America’s leadership in the global AI race by unlocking the power needed for innovation, while keeping energy sustainable and affordable.

AI is changing how customers discover and trust brands, and Profound is building the marketing infrastructure for that future. In this interview, Co‑Founder & CEO James Cadwallader shares why every company will soon care deeply about how AI talks about their brand, and why agents will become the operational layer of modern marketing. Profound already supports 10% of the Fortune 500 and major agencies with tools to monitor how brands appear across answer engines and take action to shape that narrative. With Profound Agents, the platform is moving beyond measurement into orchestration and automation, helping teams close the gap between strategy and execution.

Xanadu is building secure connections across every device, workload, and machine - laying the foundation for the quantum-powered future. According to Founder and CEO Christian Weedbrook, quantum computing is rapidly transforming the world, with breakthroughs emerging across industries such as pharmaceuticals, materials design, quantum chemistry, artificial intelligence, finance, and beyond. As these technologies evolve, Xanadu is at the forefront, enabling the secure, scalable infrastructure needed to unlock their full potential.

From florals to chocolates, for Valentine’s Day, Mother’s Day, and every occasion in between, UrbanStems is redefining the premium gifting experience. With a rotating selection of thoughtfully designed seasonal bouquets and curated gifts, the brand connects with customers in meaningful ways, meeting them wherever they are. In this video, UrbanStems CEO Meenakshi Lala shares insight into the company’s current strategy and the opportunities driving its continued growth in an evolving market.

Midi Health is addressing a long‑standing gap in healthcare by delivering specialized care for women nationwide. The platform supports women across a broad range of health needs, providing care for thousands of patients and helping them feel better, stay resilient, and perform at their best – at work, at home, and everywhere in between. In this interview, Joanna Strober, Co-Founder & CEO of Midi Health, shares how the company is expanding access to specialized women’s healthcare across the country – and why she believes the future of care is virtual.

From transforming workflows to creating next‑generation AI agents, Torq is redefining modern security operations — making them faster, more scalable, and more intelligent. In this episode, Torq CEO Ofer Smadari dives into how Torq drives AI‑powered automation across the SOC and what’s coming next.